For diabetes mellitus (DM), one of the most prevalent chronic disease entities, different pathophysiological mechanisms can be identified. Next to the most common form of type II DM (T2DM), type I diabetes (T1DM), gestational diabetes (GDM) and iatrogenic DM, mainly caused by drug-induced disturbances of glucose homeostasis, can be distinguished. Obviously, therapies to combat DM should be tailored to the underlying pathophysiology . Furthermore, hyperglycemia and other phenomena of DM are risk factors to develop (premature) cardiovascular disease.
In this course, students will learn how to identify key factors in the pathophysiology of diabetes, evaluate currently available compounds related to the underlying pathophysiology, and critically evaluate emerging therapies. To this end, students will learn to assess the value and limitations of animal models and human disease models. In addition to theory, the students will meet patients with diabetes and learn about their difficulty coping with the disease and its sequela. It is expected that the students will develop pharmacology-based ‘solutions’ for the problems that the patients will present to them.
The course will be held at the Centre for Human Drug Research (Zernikedreef 8, Leiden) and will consists of lectures, patient demonstrations, literature reviews and self-study assignments.
Prof. dr. J (Koos) Burggraaf
Students of Bio-Pharmaceutical Sciences.
Lectures / self study / case-studies.
Will be announced during the lectures.
Presentation, verbal examination and report (due on May 9th 2014).
This course is rescheduled to start on April 28th 2014.
Minimum of 5 students (max. 9 students will be admitted)